Welcome!

News Feed Item

Hanger Reports Second Quarter 2014 Financial Results

AUSTIN, Texas, Aug. 7, 2014 /PRNewswire/ --

  • 3.0% Net Sales Growth
  • Adjusted Diluted EPS of $0.40
  • Diluted EPS of $0.35

Hanger, Inc. (NYSE: HGR) today announced its preliminary financial results for the second quarter 2014. Net sales were $275.9 million for the quarter ended June 30, 2014, an increase of $8.1 million from net sales of $267.8 million for the second quarter of 2013. Adjusted diluted earnings per share were $0.40 for the second quarter of 2014, compared to second quarter 2013 adjusted diluted earnings per share of $0.52. Adjusted EPS excludes non-recurring tax costs, costs related to acquisitions, debt issuance costs associated with the June 2013 refinancing of the Company's bank credit facilities, severance costs related to a reduction in force, costs related to executive management changes and costs related to the implementation of the Company's new clinic management system (which the Company refers to as "Janus"). Diluted earnings per share were $0.35 for the second quarter of 2014 compared to $0.40 for the same period of 2013.

The net sales increase of $8.1 million, or 3.0%, for the second quarter was the result of a $6.8 million, or 3.0%, increase in the Patient Care segment, and a $1.3 million, or 3.1%, increase in the Products & Services segment. The $6.8 million increase in Patient Care segment sales was comprised primarily of a $10.6 million increase in sales from acquisitions, partially offset by a $3.2 million, or 1.5%, decline in same center sales. The Company attributes the reduction in same center sales largely to a slow-down in prosthetic patient flow driven by a slowdown in authorizations from payors and postponement of discretionary spending decisions by patients, and a slowdown in payments, which requires increased accounts receivable reserves and lowers net sales.

Income from operations for the quarter ended June 30, 2014 was $26.4 million, compared to $36.6 million in the prior year. Adjusted income from operations for the second quarter, which excludes non-recurring tax costs, costs related to acquisitions, severance costs related to a reduction in force, costs related to executive management changes and the implementation of Janus, was $28.9 million, compared to $43.7 million in the prior year. The decline in adjusted income from operations was driven principally by the decline in same center sales in the Patient Care segment, continued losses in the Company's post-injury O&P patient services business (Dosteon) and investments the Company has made in its finance and revenue cycle management operations to improve processes and controls.

Net sales for the six months ended June 30, 2014 increased $14.4 million, or 2.9%, to $511.5 million from $497.1 million in 2013. The sales increase was driven primarily by a $13.4 million increase in the Patient Care segment, which consisted of a $20.6 million increase from acquired O&P entities partially offset by a decline in same-center sales of $6.1 million, or 1.5%, and an increase of $1.0 million, or 1.2%, in the Products & Services segment. Diluted earnings per share were $0.52 for the first six months of 2014 compared to $0.67 for the same period of 2013. Adjusted diluted earnings per share, which excludes costs related to acquisitions, the implementation of Janus, and debt issuance cost associated with the June 2013 refinancing of the Company's bank credit facilities, was $0.59 for the first six months of 2014 compared to adjusted diluted earnings per share of $0.80 for the first six months of 2013.

For the six months ended June 30, 2014, the Company reported a $7.5 million net outflow of cash from operations, compared to a $27.6 million cash inflow from operations for the same period in 2013. The reduction in cash flow from operations compared to the previous year is primarily a result of lower net income and $46.7 million of increased working capital. The increase in working capital was primarily due to an increase in accounts receivable and inventory balances. The increase in accounts receivable included the impact of increased Medicare audits, which caused the Company's Medicare receivables over 120 days old to increase by $14.0 million year-over–year. Accounts receivable was also impacted by the roll out of the Company's Janus system, which impacted receivable collection efforts in patient care centers as employees were trained and adapted to the new workflow associated with the system. Inventory balances increased as work in process grew due to a combination of the impact of acquisitions and a slowdown in the payor authorization process, which has increased the average length of time it take to deliver a patients device. As of June 30, 2014 the Company had $111.3 million in total liquidity, including $4.9 million of cash and $106.4 million available under its revolving credit facility, net of $90.0 million of borrowings and $3.6 million in letters of credit. The Company's leverage ratio, as defined in its credit facilities, was 3.1 times as of June 30, 2014.

"We are clearly disappointed with our second quarter results and are revising our outlook for the year," commented Vinit Asar, President and Chief Executive Officer. "The continuing pressure on authorizations, collections and patient flow has had a significant impact on our top and bottom line to date, and will continue to pressure our earnings growth at least through the remainder of this year. We have already begun meeting these challenges head-on by increasing our focus on business development and implementing cost reductions, including a reduction in force, and the rationalization of certain investments and other cost-savings measures. While this is certainly a difficult environment today, we remain confident that the fundamental growth prospects of our market and our strategy and execution capabilities will deliver significant long-term returns for our shareholders."  Mr. Asar continued, "Over the past two quarters we've been carefully evaluating the results of our Dosteon and CARES businesses and have determined that parts of these businesses may not provide strategic long-term value. We are in the process of evaluating restructuring alternatives for these businesses."

The Company lowered its 2014 full-year adjusted diluted EPS guidance to a range of between $1.60 and $1.70. Based on the results of the second quarter, the Company now believes that the conditions that resulted in lower same-center sales in the second quarter will continue to impact its sales and operations for the remainder of 2014, resulting in lower sales and earnings projections for the year. The Company now expects that same center sales for the second half of 2014 will be flat to down 2%. Consequently, the Company is revising its same center sales for the full year to a range of a decline of 1% to 2%. The reduction in earnings projections principally reflects lower same center sales in the Patient Care segment, and to a lesser degree the impact on sales and collections of the Janus roll-out, costs incurred to remediate the Company's previously reported material weaknesses and investments the Company is making in its processes and control environment. The Company lowered 2014 full-year net sales guidance to a range of between $1.050 and $1.080 billion. The expectation of negative same center sales will be partially offset by additional acquisitions which will drive incremental revenues for the remainder of the year, but will not provide significant earnings over that period due to their initial integration costs. Reflecting the lower than expected first half results, the impact of the reimbursement environment on working capital, the Company has adjusted its expectation of 2014 cash flow from operations to a range of between $40 and $50 million. The Company now anticipates acquiring O&P operations in 2014 with annualized net sales of between $50 and $60 million, and plans to invest between $40 and $50 million in capital additions during the year.  The Company's previous full-year 2014 guidance issued on May 5, 2014 was to achieve revenues of $1.100 to $1.120 billion, adjusted diluted EPS of $2.01 and $2.11, patient care same center sales of 2% to 4%, and cash flow from operations of $80 to $90 million.  The potential impact of any restructuring of the Company's Dosteon or CARES businesses is not included in the Company's 2014 guidance.

A conference call to discuss the Company's second quarter 2014 results is scheduled to begin at 9:00 a.m., ET, on Friday, August 8th, 2014. Those wishing to participate should call 1-877-662-6095. A replay will be available until Monday, August 18, 2014 by dialing 1-855-859-2056 and referencing Conference ID # 44683027.

About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market.  Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with in excess of 760 locations nationwide.  Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. Steeped in over 150 years of clinical excellence and innovation, Hanger's vision is to be the partner of choice for products and services that enhance human physical capability.  For more information on Hanger, visit www.hanger.com and follow us at www.Facebook.com/HangerNews, www.Twitter.com/HangerNews, and www.YouTube.com/HangerNews

This document contains forward-looking statements relating to the Company's results of operations.  The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements.  Statements relating to future results of operations in this document reflect the current views of management.  However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products, the impact of reviews, audits and investigations conducted from time to time by governmental agencies, and the other factors identified in Item 1A, "Risk Factors" in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934.  The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Hanger, Inc.

(in thousands, except for share and per share amounts)

(Unaudited)










Three Months Ended


Six Month Ended


June 30,


June 30,

Income Statement:

2014


2013


2014


2013

Net sales

$                275,854


$                267,798


$                511,459


$                497,148

Material costs

84,244


79,446


151,589


147,184

Personnel costs

101,964


93,176


198,395


183,129

Other operating expenses

51,120


49,022


96,721


88,680

Depreciation and amortization

12,134


9,510


22,332


18,795

Income from operations

26,392


36,644


42,422


59,360

Interest expense

6,201


7,708


12,299


15,485

Extinguishment of Debt

-


6,645


-


6,645

Income before taxes

20,191


22,291


30,123


37,230

Provision for income taxes

7,572


8,212


11,507


13,661

Net income

$                  12,619


$                  14,079


$                  18,616


$                  23,569









Basic Per Common  Share Data:








Net income

$                      0.36


$                      0.40


$                      0.53


$                      0.68

Shares used to compute basic per share amounts

35,469,769


34,849,659


35,319,944


34,724,077









Diluted Per Common Share Data:








Net income 

$                      0.35


$                      0.40


$                      0.52


$                      0.67

Shares used to compute diluted per share amounts

35,591,764


35,307,697


35,470,170


35,225,871









Reconciliation of GAAP financial measures to Non-GAAP financial measures:











Income from operations

$                  26,392


$                  36,644


$                  42,422


$                  59,360

Acquisition expenses

355


179


583


252

Janus expenses

893


202


1,455


587

RIF - Severance

601


-


601


-

Sr. Mgmt Changes

675


-


675


-

Extinguishment of Debt

-


6,645


-


6,645

Adjusted Income from operations

$                  28,916


$                  43,670


$                  45,736


$                  66,844









Net income 

$                  12,619


$                  14,079


$                  18,616


$                  23,569

Acquisition expenses

355


179


583


252

Janus expenses

893


202


1,455


587

RIF - Severance

601


-


601


-

Sr. Mgmt Changes

675


-


675


-

Extinguishment of Debt

-


6,645


-


6,645

Tax effect of adjustments

(946)


(2,586)


(1,239)


(2,747)

Non-recurring tax benefit (cost)

8


-


248


-

Adjusted net income 

$                  14,205


$                  18,519


$                  20,939


$                  28,306









Adjusted net income per diluted share

$                      0.40


$                      0.52


$                      0.59


$                      0.80


















Three Months Ended


Six Month Ended


June 30,


June 30,

Income Statement as a % of Net Sales:

2014


2013


2014


2013

Net sales

100.0%


100.0%


100.0%


100.0%

Material costs

30.5%


29.7%


29.6%


29.6%

Personnel costs

37.0%


34.8%


38.8%


36.9%

Other operating expenses

18.5%


18.3%


18.9%


17.8%

Depreciation and amortization

4.4%


3.5%


4.4%


3.8%

Income from operations

9.6%


13.7%


8.3%


11.9%

Interest expense

2.3%


2.9%


2.4%


3.1%

Extinguishment of Debt

0.0%


2.5%


0.0%


1.3%

Income before taxes

7.2%


8.3%


5.9%


7.5%

Provision for income taxes

2.7%


3.0%


2.2%


2.8%

Net income 

4.6%


5.3%


3.6%


4.7%









Adjusted income from operations

10.5%


16.3%


8.9%


13.4%

Adjusted net income

5.1%


6.9%


4.1%


5.7%

 

Hanger, Inc.


(in thousands, except for statistical data)


(Unaudited)














Three Months Ended


Six Months Ended




June 30,


June 30,


Cash Flow Data:


2014


2013


2014


2013


Cash flow provided by operations 


$                        2,476


$                     25,451


$                      (7,485)


$                      27,644


Capital expenditures


$                      12,825


$                     12,679


$                      21,686


$                      18,045


Increase/(decrease) in cash and cash equivalents


$                    (50,722)


$                      (9,299)


$                      (4,958)


$                    (13,445)






















Balance Sheet Data:






June 30, 2014


December 31, 2013


Cash and cash equivalents






$                        4,902


$                        9,860


Days Sales Outstanding (DSO's) *






72


65


Working Capital 






$                    313,817


$                    267,085


Total Debt






$                    539,889


$                    468,259


Shareholders' Equity






$                    607,312


$                    580,220












*excludes acquired accounts receivable balances












Three Months Ended


Six Months Ended




June 30,


June 30,




2014


2013


2014


2013


Revenue Mix:










Patient Care


84.1%


84.1%


83.6%


83.3%


Products & Services


15.9%


15.9%


16.4%


16.7%






















Patient Care Payor Mix:










Commercial and other


57.8%


58.6%


59.3%


59.0%


Medicare


29.4%


29.7%


28.5%


29.4%


Medicaid


6.1%


5.4%


5.6%


5.3%


VA


6.7%


6.3%


6.6%


6.4%


 

Management relies on the non-GAAP items as the primary measures to review and assess operating performance and management teams. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. Management and investors also review the non-GAAP items to evaluate the Company's overall performance and to compare its current operating results with corresponding periods and with other companies in the health care industry. You should not consider the non-GAAP items in isolation or as a substitute for net income, operating cash flows or other cash flow statement data determined in accordance with accounting principles generally accepted in the United States. Because the non-GAAP items are not measures of financial performance under accounting principles generally accepted in the United States and are susceptible to varying calculations, they may not be comparable to similarly titled measures of other companies. Adjusted net income, Adjusted income from operations, and Adjusted net income per diluted share are the non-GAAP financial measures.

 

SOURCE Hanger, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
"We were founded in 2003 and the way we were founded was about good backup and good disaster recovery for our clients, and for the last 20 years we've been pretty consistent with that," noted Marc Malafronte, Territory Manager at StorageCraft, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU's GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes. In...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessio...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Announcing Poland #DigitalTransformation Pavilion
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
CloudEXPO | DXWorldEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.